CG MedTech Co.,Ltd. (KOSDAQ:056090)
South Korea · Delayed Price · Currency is KRW 2,165.00
0.00 (0.00%)
At close: Feb 19, 2026
CG MedTech Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 45,591 | 34,623 | 34,969 | 41,169 | 38,055 | 27,775 |
Other Revenue | -0 | -0 | -0 | -0 | - | -0 |
| 45,591 | 34,623 | 34,969 | 41,169 | 38,055 | 27,775 | |
Revenue Growth (YoY) | 28.84% | -0.99% | -15.06% | 8.18% | 37.01% | -20.22% |
Cost of Revenue | 25,367 | 18,834 | 17,139 | 22,518 | 22,571 | 21,932 |
Gross Profit | 20,225 | 15,789 | 17,829 | 18,651 | 15,484 | 5,843 |
Selling, General & Admin | 11,964 | 12,430 | 13,952 | 12,638 | 10,525 | 11,599 |
Research & Development | 3,357 | 3,357 | 4,462 | 4,471 | 4,893 | 4,462 |
Amortization of Goodwill & Intangibles | 86.48 | 86.48 | 97.52 | 106.96 | 137.85 | 100.26 |
Other Operating Expenses | 127.64 | 127.64 | 117.83 | 143.14 | 126.68 | 103.54 |
Operating Expenses | 16,852 | 16,885 | 15,626 | 28,828 | 16,299 | 16,647 |
Operating Income | 3,373 | -1,096 | 2,204 | -10,177 | -815.21 | -10,805 |
Interest Expense | -185.71 | -185.71 | -535.88 | -6,317 | -1,294 | -1,242 |
Interest & Investment Income | 571.87 | 571.87 | 374.56 | 592.34 | 102.16 | 132.34 |
Earnings From Equity Investments | 15.75 | 15.75 | - | - | - | - |
Currency Exchange Gain (Loss) | 691.8 | 691.8 | 148.54 | 382.6 | 490.54 | -95.31 |
Other Non Operating Income (Expenses) | -328.54 | 141.31 | -262.14 | -3,896 | -160.49 | 73.72 |
EBT Excluding Unusual Items | 4,138 | 138.85 | 1,929 | -19,416 | -1,677 | -11,936 |
Gain (Loss) on Sale of Investments | -258.52 | -258.52 | -340.46 | 672.25 | 191.93 | -166.86 |
Gain (Loss) on Sale of Assets | 132.53 | 132.53 | 261.96 | 165.77 | 23.41 | -5.03 |
Asset Writedown | - | - | -463.9 | - | -3,944 | - |
Other Unusual Items | - | - | - | 156.54 | - | - |
Pretax Income | 4,012 | 12.86 | 1,387 | -18,421 | -5,406 | -12,108 |
Income Tax Expense | 184.15 | 137.79 | 80.88 | 386.87 | -190.67 | 175.05 |
Earnings From Continuing Operations | 3,828 | -124.94 | 1,306 | -18,808 | -5,215 | -12,283 |
Minority Interest in Earnings | 21.3 | 184.63 | 323.44 | 268.83 | 244.37 | - |
Net Income | 3,849 | 59.69 | 1,629 | -18,540 | -4,970 | -12,283 |
Net Income to Common | 3,849 | 59.69 | 1,629 | -18,540 | -4,970 | -12,283 |
Net Income Growth | - | -96.34% | - | - | - | - |
Shares Outstanding (Basic) | 118 | 94 | 79 | 67 | 45 | 38 |
Shares Outstanding (Diluted) | 118 | 94 | 79 | 67 | 45 | 38 |
Shares Change (YoY) | 75.42% | 18.97% | 18.55% | 49.47% | 16.01% | 0.40% |
EPS (Basic) | 32.60 | 0.64 | 20.65 | -278.64 | -111.66 | -320.10 |
EPS (Diluted) | 32.60 | 0.64 | 20.65 | -279.00 | -112.00 | -320.10 |
EPS Growth | - | -96.92% | - | - | - | - |
Free Cash Flow | -4,592 | 736.7 | -4,068 | -6,184 | 375.08 | 1,945 |
Free Cash Flow Per Share | -38.90 | 7.85 | -51.58 | -92.95 | 8.43 | 50.70 |
Gross Margin | 44.36% | 45.60% | 50.99% | 45.30% | 40.69% | 21.04% |
Operating Margin | 7.40% | -3.17% | 6.30% | -24.72% | -2.14% | -38.90% |
Profit Margin | 8.44% | 0.17% | 4.66% | -45.03% | -13.06% | -44.22% |
Free Cash Flow Margin | -10.07% | 2.13% | -11.63% | -15.02% | 0.99% | 7.00% |
EBITDA | 5,239 | 596.09 | 4,057 | -7,977 | 1,347 | -8,398 |
EBITDA Margin | 11.49% | 1.72% | 11.60% | -19.38% | 3.54% | -30.24% |
D&A For EBITDA | 1,866 | 1,692 | 1,853 | 2,201 | 2,162 | 2,406 |
EBIT | 3,373 | -1,096 | 2,204 | -10,177 | -815.21 | -10,805 |
EBIT Margin | 7.40% | -3.17% | 6.30% | -24.72% | -2.14% | -38.90% |
Effective Tax Rate | 4.59% | 1071.82% | 5.83% | - | - | - |
Advertising Expenses | - | 85.15 | 351.37 | 311.16 | 176.3 | 209.98 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.